Clinical and paraclinical aspects of pregnancy, that is complicated by a retrochorial hematoma

Authors

  • В. І. Пирогова Lviv National Medical University named after Danilo Galickyi, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2014.19.108-110

Keywords:

retrochorial hematoma, miscarriage, micronized progesterone, Utrozhestan

Abstract

May 15–16, 2014 in Kiev, at the conference «Harmony of hormones – the basis of the woman’s health» was heard a report on the clinical and paraclinical aspects of pregnancy that is complicated retrochorial hematoma.

Retrochorial hematomas are one of the causes of miscarriage. After the diagnosis of retrochorial hematoma tactics must be based on progestin therapy to maintain pregnancy and prevent further complications. Administration of progesterone for 2–3 months before a planned pregnancy is an optimal primary prevention. For this purpose micronized progesterone Utrozhestan is vaginally used in clinical practice

Author Biography

В. І. Пирогова, Lviv National Medical University named after Danilo Galickyi

MD, Professor, Head of Department of Obstetrics, Gynecology and Perinatology, Faculty of Continuing Education

References

  1. Maso G., D’Ottavio G., de Seta F. et al. «First-trimester intrauterine hematoma and outcome of pregnancy.» Obstetrics and Gynaecology, 105(2) (2005):339-344.
  2. Vaisbuch E., de Ziegler D., Leong M., Weissman A., Shoham Z. «Luteal-phase support in assisted reproduction treatment: real-life practices reported worldwide by an updated website based survey.» Reprod. Bio med Online. 2014 Mar; 28(3):330-5.

Downloads

Published

2014-10-20

How to Cite

Пирогова, В. І. (2014). Clinical and paraclinical aspects of pregnancy, that is complicated by a retrochorial hematoma. REPRODUCTIVE ENDOCRINOLOGY, (19), 108–110. https://doi.org/10.18370/2309-4117.2014.19.108-110

Issue

No. 19 (2014)

Section

Events

License

Copyright (c) 2015 В. І. Пирогова

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.